TINN2 is a European research network (Collaborative Project) supported by the European Commission under the Health Cooperation Work Programme of the 7 th Framework Programme.

News & Events

 

TINN European Survey on the Use of Antibiotics in NICUs

The survey results are now available and the published article has been published.

Please click here to consult it.

 

MANY THANKS to all the Neonatal Intensive Care Units that dedicated their time to partipate in the TINN2 survey.

 

Consortium final meeting on 8th October 2015, in Paris, France

The official event of the TINN2 FP7 European Research Project was organised by Inserm-Transfert on 8th October 2015 in Paris (France).

This meeting gathered together all TINN2 partners for presenting and discussing the latest progresses within TINN2 activities, a project on preclinical studies and paediatric investigation plans for children, under the coordination of the French National Institute of Health and Medical Research (Inserm).

European Congress of Clinical Microbiology and Infectious Diseases, London, United Kingdom 31st to 4th April 2012

 

TINN2 Project was presented on Poster at the ECCMID congress in London, United Kingdom.

Brochure PDF :

Centre Hospitalier Chrétien

The Centre Hospitalier Chrétien (CHC) is the biggest private hospital entity in Belgium (102 paediatric beds out of 1051 overall acute beds) and is partly affiliated to the Catholic University of Louvain (UCL) through the Commission du Réseau Hospitalier Universitaire (CRHU). A Neonatal Intensive Care Unit (NICU) (35 beds, Head: Dr Maton) is being fully part of the Paediatric Department (Head: Dr P Philippet).

 

This CHC-NICU is experienced in pharmacological clinical trials in preterms and neonates

- aminoglycosides PKs study in VLBW infants and therapeutic schedule proposal

- participation in a multicenter clinical trial (prophylactic Ibuprofen in VLBW infants vs placebo)

- participation in a multicenter clinical trial prospective trial comparing indometacin and ibuprofen as a treatment of the patent ductus arteriosus (PDA)

- ongoing multicenter trial using prophylactic low dose of inhaled NO in preventing bronchopulmonary dysplasia in ELBW infants.

 

Jean-Paul Langhendries is Paediatrician and Neonatologist, working in the Neonatal Intensive Care Unit (NICU) of the CHC hospital entity in close collaboration with Drs Maton , Marguglio and François-Adant neonatalogists. He received a MD degree at the Catholic University of Louvain (UCL,1976), a paediatric license at the same university (1981), a Master Degree in Pharmacology and Pharmaceutical Industry (Pharmed) from the Free University of Brussels (ULB, 1995). He was formerly at the Head of the Neonatal Department of the Clinique St Vincent in Rocourt-Liège from 1982 to 1998. He was formerly President of the European Society for Developmental Perinatal & Paediatric Pharmacology (ESDP) from 2000 to 2002 and is an active member of the European Network for Drug Investigation (ENDIC) which is a working-group of the ESDP. He was a member of the Paediatric Expert Group (PEG), an ad-hoc sub-group of the Committee for Proprietary Medicinal Products (CPMP) at the EMEA from 2001 to 2007. He is an active member of the Mother-Infant College (Peer Review) at the Ministry of Public Health in Belgium. He is a member of the Bioethical Committee of the Hospital CHC-Site St Vincent. His fields of interest are paediatric and neonatal pharmacology, neonatal infectious diseases and neonatal nephrology.

 

Back to the list of institutions